What question did this study set out to answer?

The aim is to assess how effective and safe pimavanserin is for treating psychosis in Parkinson’s disease.

June 13, 2026

Pimavanserin for Parkinson’s Disease Psychosis: A Meta-analysis of Placebo-controlled Randomized Trials (P3-17.013)

MPMatthew George PetruncioCooper Medical School of Rowan University JRJamir Pitton RissardoCooper University Hospital OEOmar ElmandouhCooper University Hospital

Key Points

The aim is to assess how effective and safe pimavanserin is for treating psychosis in Parkinson’s disease.
Conducted a meta-analysis of placebo-controlled randomized controlled trials.
Evaluated multiple studies focusing on pimavanserin and its impact on Parkinson’s disease psychosis.
Included trials assessing efficacy and safety outcomes.
Pimavanserin significantly reduced psychotic symptoms in patients compared to placebo.
Safety profile was consistent with previous studies, with no new safety concerns identified.

Abstract

To evaluate the efficacy and safety of pimavanserin in Parkinson’s disease psychosis (PDP) through a meta-analysis of placebo-controlled randomized controlled trials (RCTs).

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Petruncio et al. (Tue,) studied this question.

synapsesocial.com/papers/6a2cf300faef96ed7f0559b2 https://doi.org/https://doi.org/10.1212/wnl.0000000000215026

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper